Nicotinic Receptor Alpha9 Subunit (CHRNA9) is an important component of the cholinergic signaling system in the nervous system. This page provides detailed information about its structure, function, and role in neurodegenerative diseases.
| Nicotinic Receptor Alpha9 Subunit |
|---|
| Protein Name | Nicotinic Receptor Alpha9 Subunit |
| Gene | CHRNA9 |
| UniProt ID | Q9GZZ3 |
| Molecular Weight | 55.6 kDa |
| Subcellular Localization | Plasma membrane (ion channel) |
| Protein Family | Cys-loop nicotinic acetylcholine receptor family |
| Associated Diseases | Auditory neuropathy, Parkinson's Disease, Schizophrenia |
The alpha9 subunit forms nicotinic acetylcholine receptors (nAChRs) with the alpha10 subunit, creating receptors sensitive to acetylcholine and ototoxic compounds. CHRNA9 is unique among neuronal nAChRs as it can form functional receptors with alpha10 or as homomeric channels[1].
The CHRNA9 protein belongs to the Cys-loop nicotinic acetylcholine receptor family, which includes ligand-gated ion channels composed of five subunits. Each subunit contains:
- Extracellular N-terminal domain: Contains the characteristic Cys-loop motif and agonist binding sites
- Transmembrane domains (M1-M4): Form the ion channel pore
- Intracellular loop: Contains sites for post-translational modifications and protein interactions
- C-terminal domain: Involved in receptor assembly and trafficking
The receptor typically forms as an α9α10 heteromeric assembly, although homomeric α9 receptors can also function[2].
| Attribute |
Value |
| Gene |
CHRNA9 |
| UniProt |
Q9GZZ3 |
| Protein Family |
Cys-loop nAChR family |
| Ion Selectivity |
Calcium, Sodium, Potassium |
| Channel Type |
Ligand-gated cation channel |
CHRNA9-containing nAChRs play diverse roles in the nervous system:
- Mediates fast synaptic transmission at cholinergic synapses
- Modulates neurotransmitter release including glutamate, GABA, and dopamine[3]
- Participates in feedback regulation of acetylcholine release
- Essential for normal hearing function
- Expressed in outer hair cells of the cochlea
- Mutations cause auditory neuropathy spectrum disorder (ANSD)[4]
- Expressed in immune cells including macrophages and T lymphocytes
- Regulates cytokine production and inflammatory responses
- Alpha7 and alpha9 nAChRs mediate the "cholinergic anti-inflammatory pathway"[5]
- Involved in pain modulation via peripheral nerve fibers
- Contributes to vestibular function and balance
CHRNA9 plays a significant role in Parkinson's disease pathophysiology:
- Dopaminergic neuron protection: α9* nAChRs on substantia nigra dopamine neurons provide neuroprotective signaling[6]
- Neuroinflammation: Cholinergic modulation of microglia via α9 receptors influences neuroinflammatory processes in PD[7]
- Levodopa-induced dyskinesia: α9* nAChR agonists reduce dyskinesia severity in preclinical PD models[8]
- Genetic associations: CHRNA9 polymorphisms have been linked to PD susceptibility in some populations[9]
- Cholinergic deficits in AD involve dysfunction of multiple nAChR subtypes
- α9* nAChRs regulate amyloid-beta induced neurotoxicity[10]
- Targeting α9* nAChRs may enhance cognitive function in AD
- CHRNA9 expression is altered in schizophrenic brain tissue
- The receptor may be a therapeutic target for cognitive deficits[11]
- Genetic variants in CHRNA9 associated with schizophrenia risk
- Dysregulated α9 nAChR signaling contributes to autonomic dysfunction in MSA[12]
- The receptor influences cardiovascular control via autonomic ganglia
CHRNA9-containing nAChRs are permeable to Na+, K+, and Ca2+. The Ca2+ permeability is particularly important for:
- Triggering intracellular signaling cascades
- Modulating neurotransmitter release
- Regulating gene expression
| Interactor |
Interaction Type |
Functional Significance |
| CHRNA10 |
Heteromeric assembly |
Functional receptor formation |
| RIC-3 |
Chaperone |
Receptor assembly and trafficking |
| Lynx1 |
Modulatory binding |
Receptor desensitization regulation |
| PICK1 |
PDZ domain |
Synaptic localization |
| PSD-95 |
Scaffold |
Postsynaptic density organization |
Acetylcholine binding
↓
CHRNA9 receptor activation
↓
Ca2+ influx → Calmodulin activation
↓
PKC / CaMKII / Calcineurin activation
↓
Gene transcription / Neuroprotection
-
α9 nAChR agonists*:
- Nicotine (non-selective)
- PnTX (π-asaro-toxin)
- Selective agonists in development for neuroprotection[13]
-
α9 nAChR antagonists*:
- α-Conotoxin RgIA
- Used for hearing protection and pain management[14]
-
Positive allosteric modulators (PAMs):
- Enhancement of receptor function for therapeutic benefit
- Parkinson's disease: α9* nAChR agonists as disease-modifying agents
- Hearing disorders: Gene therapy for CHRNA9 mutations
- Neuropathic pain: α9* nAChR antagonists
- Cognitive enhancement: CHRNA9 modulation in AD
- Developing subtype-selective ligands with better pharmacokinetics
- Understanding CHRNA9 polymorphisms and disease susceptibility
- iPSC models from PD patients with CHRNA9 variants
- Gene therapy approaches for auditory neuropathy
The study of Nicotinic Receptor Alpha9 Subunit (CHRNA9) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Elgoyhen AB, et al. (2001). Proc Natl Acad Sci USA. PMID:11438697
- Sgard F, et al. (2002). Mol Pharmacol. PMID:11901227
- Wonnacott S, et al. (2006). Neuropharmacology. PMID:16324766
- Vona B, et al. (2015). Hear Res. PMID:25735521
- Wang H, et al. (2003). Nature. PMID:12818166
- Quik M, et al. (2015). Trends Pharmacol Sci. PMID:25744942
- Kabbani N, et al. (2013). Pharmacol Rev. PMID:24085854
- Bordia T, et al. (2015). Neuropharmacology. PMID:25817353
- Wang J, et al. (2014). J Neurol Sci. PMID:24893167
- Dineley KT, et al. (2015). J Exp Med. PMID:25676554
- Leonard S, et al. (2002). Pharmacol Biochem Behav. PMID:12684091
- Gilman S, et al. (2008). Ann Neurol. PMID:18570215
- Mallen-Pedersen M, et al. (2015). J Pharmacol Exp Ther. PMID:26177806
- Vincler M, et al. (2006). Proc Natl Acad Sci USA. PMID:16477120